Post-RC Radiation Does Not Up Survival in Locally Advanced Bladder Cancer
Further studies are needed to evaluate oncologic outcomes after postoperative radiation therapy.
Further studies are needed to evaluate oncologic outcomes after postoperative radiation therapy.
Investigators report a 24-month recurrence-free survival rate of 82% with the use of intravesical gemcitabine/docetaxel following complete transurethral resection of bladder tumor.
Investigators said the findings of their cross-sectional study “highlight the power as well as the limitations of prominent RCTs.”
Large differences in risks for severe adverse events according to sex seen for cancer patients receiving immunotherapy
In a study, approximately half of patients with and without stage 3a CKD maintained their renal function after orthotopic neobladder formation.
Increasing T stage has been associated with reduced long-term survival after trimodal therapy.
Neoadjuvant enfortumab vedotin demonstrated promising initial results in a small number of cisplatin-ineligible patients with muscle-invasive bladder cancer, according to investigators.
Sequential intravesical gemcitabine and docetaxel could provide an effective treatment option during an ongoing BCG shortage.
In a phase 2 trial, 44% of men who received abiraterone with or without cabazitaxel prior to radical prostatectomy for high-risk prostate cancer achieved a pathologic complete response or minimal residual disease.
Computed tomography scans following neoadjuvant chemotherapy for muscle-invasive bladder cancer does not accurately predict disease burden prior to radical cystectomy.